|
Manhattan Pharmaceuticals, Inc., (OTCBB: MHAN) is a pharmaceutical company that acquires and develops novel, high value drug candidates primarily for the treatment of dermatologic and immune disorders. With a pipeline consisting of four clinical stage product candidates, Manhattan Pharmaceuticals is developing potential therapeutics for large, underserved patient populations seeking superior treatments for conditions including pediculosis, (head lice), psoriasis, pruritus associated with atopic dermatitis (eczema), and mastocytosis.
|
| Stock Information
|
OTCBB:MHAN
$0.08
+ 0.01
|
Mar 10, 2010
3:00 PM ET |
Quotes delayed at least 20 minutes.
Information provided by eSignal.
|
